5th surfactant (lucinactant) for respiratory distress syndrome (RDS) in premature infants approved by the FDA today


bubbles in front of man The fifth surfactant to be approved to treat Respiratry Distress Syndrome (RDS) was approved by the FDA today. the new drug is called Surfaxin (lucinactant) and joins the 4 previously approved medicines for RDS. This drug was approved to prevent RDS based on one study of 1,294 premature infants. read the release at www.fda.gov.

Approval Date: 
Tue, 03/06/2012
Discovery Laboratories, Inc.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.